All treatments
Treatment
Ifinatamab Deruxtecan (I-DXd) clinical trials
2 indexed studies · 1 currently recruiting
- RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
This study is testing new medicines, Gocatamig and Ifinatamab Deruxtecan (I-DXd), for advanced small cell lung cancer that has come back or isn't responding to treatment. Researchers want to see if these drugs, alone or together, are safe and can shrink the cancer.
For: Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is testing a new drug, Ifinatamab Deruxtecan (I-DXd), for people with extensive-stage small cell lung cancer who have already had other treatments. It aims to find the best dose and see how well it works and if it's safe.
For: Extensive-stage Small-cell Lung CancerUnited States · China · France